Gabapentin Tablet
Product Images NDC 68788-8790

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8790). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Gabapentin Tablets 800mg Cv (800 mg 500s)

Gabapentin Tablets 800mg Cv (800 mg 500s)
This is a description for Gabapentin tablets 800mg. The tablets are oval, white, scored, and imprinted with the letter "T". Manufactured by Ascent Pharmaceuticals, Inc., this medication is the generic for Neurontin. Each tablet contains 800mg of gabapentin and should be stored at 25°C (77°F) with excursions permitted to 15° to 30°C (59 to 86°F). It is available in different package sizes, with specific expiration dates, lot numbers, and batch numbers. This medication should be kept out of the reach of children and should only be used as directed by a healthcare provider. The text also contains caution against transferring the drug to anyone other than the patient for whom it was prescribed. Additionally, there are instructions in Spanish for the dosage and frequency of the tablets.*
FDA Label Image

Clcr (Equation)

Clcr (Equation)
This is a medical formula for calculating Creatinine Clearance (CLCr) based on age, weight, and serum creatinine levels. The formula is adjusted for female patients by multiplying the result by 0.85. The calculation involves the individual's age in years multiplied by their weight in kilograms and then multiplied by 72 times the serum creatinine level in mg/dL.*
FDA Label Image

Figure-1 (Figure1)

Figure-1 (Figure1)
This is a figure showing the weekly mean pain scores in the ITT population for Study 1. The pain scores are observed over a period of 8 weeks and are presented for a treatment group receiving 3500 mg of Gabapentin. The figure provides an insight into the changes in pain scores over time.*
FDA Label Image

Figure-2 (Figure2)

Figure-2 (Figure2)
FDA Label Image

Figure-3 (Figure3)

Figure-3 (Figure3)
This text provides information on the proportion of responders in controlled postherpetic neuralgia (PHN) studies, showing the percentage reduction in pain scores. The data includes details on Study 1 and Study 2 comparing different treatments such as PBO, GBP 1800, and GBP 2400. It illustrates the response rates of patients with greater than 50% reduction in pain scores at the study endpoint.*
FDA Label Image

Figure-4 (Figure4)

Figure-4 (Figure4)
This description is not-available.*
FDA Label Image

Struc (Struct)

Struc (Struct)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.